Surabaya

Researchers are evaluating whether the medicine tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after they were last seen well. This study focuses on people who had a stroke caused by a clot blocking blood flow in the brain and who have imaging showing brain tissue that can still be saved. Participants should not be planning to receive a procedure to remove the clot and must have a pre-stroke disability level of 0 or 1 on the modified Rankin Scale. Participants are randomly placed into two groups. One group receives a single injection of tenecteplase into a vein, while the other group receives standard medical care. The study includes adults aged 18 and over who had an acute stroke or woke up with stroke symptoms more than 4.5 hours ago. Imaging with MRI or CT is used to confirm eligibility. The study lasts about three months, starting with a hospital stay of about one week. During the study, participants have seven clinical examinations or visits to monitor their recovery and health. The last two visits may be done from home to allow remote assessments. Researchers use the modified Rankin Scale to measure disability or dependence in daily activities at 90 days after treatment. They also monitor for any side effects or health changes to compare the effects of tenecteplase against standard care.

Researchers are evaluating the effectiveness of 5-methyltetrahydrofolate (5-MTHF) compared to folic acid in increasing red blood cell (RBC) folate levels in pregnant women during their first trimester. The study is motivated by the importance of folate in preventing pregnancy complications such as neural tube defects, pre-eclampsia, and premature birth. This randomized controlled trial aims to provide insights into whether the active form 5-MTHF offers advantages over traditional folic acid supplementation in improving folate status during early pregnancy. The trial will enroll 100 pregnant women aged 25 to 35 years with gestational ages between 9 and 14 weeks. Participants will be randomly assigned to receive either 600 mcg of folic acid or 1100 mcg of 5-MTHF glucosamine salt daily in film-coated tablet form, maintaining an equal molar dose. The supplementation will continue for three months, and both groups will be monitored throughout this intervention period. Participants will undergo blood tests at the start and end of the three months to measure changes in RBC folate, plasma 5-MTHF, homocysteine, and unmetabolized folic acid levels. Researchers will assess how well each supplement increases RBC folate and the proportion of women reaching a target folate level. Ethical safeguards include informed consent, confidentiality, and the right to withdraw without penalty. The study's findings aim to guide folate supplementation recommendations for pregnant women to support healthier pregnancy outcomes.

The HYIMPACT study is a large, observational research project across seven Asian countries designed to understand how Nebilet (nebivolol) works in people with high blood pressure, also called hypertension. It focuses on how Nebilet affects blood pressure control over time, treatment adherence, quality of life, prescription habits, and heart-related outcomes. The study includes about 5,000 adults with newly diagnosed or uncontrolled hypertension, some of whom may have other heart-related conditions. Participants will either start Nebilet treatment or have been on it for no more than two weeks before joining. They will be observed regularly for up to three years, with blood pressure measurements taken at baseline, 12, 24, and 36 months. The study also compares Nebilet used alone versus in combination with other treatments, and examines the relationship between blood pressure readings taken at home and in the clinic. Throughout the study, patients will have their blood pressure monitored, complete questionnaires about medication adherence and quality of life, and provide health information including cardiovascular risk factors and lab test results when available. Researchers will track major heart events like heart attacks and strokes, and record any side effects. Data will be collected electronically to ensure quality and consistency, helping to provide real-world insights about Nebilet's role in managing hypertension over time.